Exosomes are cell-cell communicators emerging as a new paradigm for noninvasive diagnosis and prognosis of treatment response. Exosomal tetraspanin proteins like CD63, CD9 and CD81 play a critical role in sorting, selective recruitment of biomolecules, target selection, cell-specific entry, capturing, angiogenesis and vasculogenesis. These tetraspanins are being used as markers for oral, colorectal and colon cancers and glioblastoma. However, exosomal markers with robust specificity for early detection of carcinomas are the furthest along. EXO CARTA database shows the presence of CD151 in exosomes of colorectal, melanoma, ovarian and prostate cancers. CD151 preferentially targets exosomes to lung, lymph node and stroma cells. The present review discussed the possible role of tetraspanins in the formation, cargo selection, target selection and uptake of exosomes and suggests exciting new directions for future research.
INTRODUCTION
Exosomes are cell-derived nanovesicles with size of 30-120 nm.
They represent a more homogenous population, originated from endosomal pathway within multivesicular bodies and are released from cells by exocytosis. 1 Exosomes have been reported in blood, breast milk, saliva, cerebrospinal fluid (CSF), nasal secretions, malignant effusions, pleural effusion and ascites. 2 The common characteristics of exosomes include size (30-120 nm in diameter), density (1.13-1.21 g/mL), enrichment of heat shock proteins and proteins from the Rab family, Tsg101 and Alix. 3 The biological functions of exosomes include antigen presentation, immune regulation, tissue development and remodeling, and cell-cell communication. Exosomes can be used as a source for biomarkers for predicting metastatic spread, targeted drug delivery, cell free antitumor vaccination and gene therapy. 4 A large number of studies have stated the role of exosomes in cancer invasion and metastasis, evading apoptosis, drug resistance and escape from immune surveillance. 5 Exosomes are unique in their composition of lipids, mRNA, regulatory microRNAs and members of tetraspanin superfamiy. 6 Exosomes bear unique protein markers associated with endosomal pathways such CD63, CD69 and CD81, HSP70
and proteins from the Rab family, Tsg101 and Alix. 7 Exosomes also have special protein markers associated with the endosomal sorting complex required for transport, such as ALG-2-interacting protein X and tumor susceptibility gene 101 protein. 7 Regardless of their homogenous nature, exosomes mediate a wide range of effects on cells, which indicate the presence of multifunctional subpopulations of exosomes. 8 Numerous reports suggest that there is a functional transfer of miRNA-rich exosomal subpopulations. 9 Willms et al. reported that there is differential packaging of miRNAs and subsequent release of distinct subpopulations of exosome-like vesicles by cancerous cells as compared to normal cells.
Increased release of one of the subpopulations possibly resulted from changes in subendocytic pathways. Others have shown that cellular activation can alter the dynamics of exosome release by increasing the release of specific populations of vesicles. 10 Malicious exosomes secreted by cancer cells play an imperative role in tumor microenvironment (TME) maturation and cancer progression. 11 The circulating exosomes are reported as tumor biomarkers due to their unique composition which imparts stability in body fluids. 12 It is widely accepted that the process of carcinogenesis requires accumulation of changes in genetic or epigenetic levels, thereby leading to reprogramming of cell phenotype and eventually to tumor development. The appearance of initial mutations in malignant cells depends on interactions among oncogenes and external factors such as exosomes which could change the patterns of specific gene expression. 13 Tumor-derived exosomes carry cargo which angiogenesis, metastasis and immunosuppression. 15 Exosome levels in plasma and other body fluids of patients with cancer are frequently elevated as stress and hypoxia that are prevalent in the TME, which can lead to enhanced exosome secretion by tumor cells. 16, 17 It has been suggested that exosome production and release by malignant cells is regulated by the p53 protein, which is often reported to be aberrantly mutated in various types of cancer. 18 Melo et al. demonstrated that exosomes derived from breast cancer patients transformed the neighboring normal cells to malignant cells 19 (Figure 1 ).
Tetraspanins are four-transmembrane-spanning proteins with short cytoplasmic N-and C-termini and one small and one large extracellular domain, namely (EC1 and EC2), with a unique cysteine motif in EC2 domain. They are predominantly expressed on the cell surface and/or intracellular vesicle. 20 Tetraspanins are involved in cell motility, adhesion, morphogenesis, as well as cell and vesicular membrane fusion. Tetraspannins form a network with exosomal and other proteins which regulate signaling transduction pathways and formation of premetastatic sites in cancer microenvironment. Tetraspanin plays a vital element in the target cell selection of exosomes uptake that may lead to the reprogramming of target cells. Reprogrammed target cells assist premetastatic niche formation. Some of the major tetraspanins which are associated with exosomes and promote cancer cell motility, invasion, metastasis, tumor initiation, promotion, progression and angiogenesis include CD9, CD8, CD82 and CD151. 21 In view of the functional role of tetraspanins in the biogenesis, cargo selection, protein and RNA sorting, targeting and uptake, they also have a great therapeutic value. Further, increasing knowledge on functions of exosomes provides a new insight into cancer research and biomarkers for cancer progression and new treatment options. Therefore, discussing the role of tetraspanins in the regulation of biological functions in cancer will be of utmost relevance in modern molecular oncology.
Tetraspanin web proteins in exosome formation
Tetraspanins are a family of scaffolding membrane proteins. They form specialized scaffolds on the exosome membrane for the compartmentalization of receptors and signaling proteins, playing a role in the sorting and selective recruitment of several proteins and possibly RNA.
Several tetraspanins are highly enriched in exosomes and contribute in key functions of exosomes. 22 Exosomal tetraspanins shuttle between host cell and recipient cell via endocytosis and potentially affect the recipient cell. 23 The study by Colombo et al. illustrated that disrupting tetraspanins result in the decreased production of exosomes in vitro. Logozzi and coworkers reported that tetraspanin positive exosomes are significantly increased in melanoma patients. 24 Yoshioka and Ochiya found that tetraspanins are present at higher levels in the exosomes derived from malignant cancer cells. 25 
Tetraspanin web proteins in target selection and uptake of exosomes
Exosome-uptake is a selective process dictated by the exosomal tetraspanin web and defined by acceptor cell ligands which are located in internalization-prone microdomains. Exosomal tetraspanins play a critical role in target selection. 23 Surface expression of adhesion tetraspanin-integrin complexes on exosomes plays a key role in target cell-specific entry. 26 In addition, some tetraspanins are used for capturing of exosomes. 27 Individual tetraspanins may separately integrate into exosomes making use of distinct fission and fusion machineries and organizing a web/recruiting molecules distinct from those in resting cells. Tetraspanin-mediated fine tuning of exosomes plays a vital role in transfer of exosomal messages to other cell. For example, CD9-and/or CD81-deficient eggs cannot fuse with sperms 28 and several viruses and parasites essentially depend on distinct tetraspanins for cell entry and spread which may involve exosomal message transfer. 29 Tetraspanin 8-associated 4 integrin complex promotes angiogenesis by promoting exosomal uptake by endothelial cells, suggesting that exosomal tetraspanin-complexes can play a key role in target selection. 30 Tetraspanin enriched microdomain (TEM) or tetraspanin web exhibit preferential binding of exosomes to endothelial cells. 31 In some scenarios, TEMs represent an alternative route of endocytosis, as reported for the entry of some viruses. 32 Moreover, TEM regulates several fusion-dependent processes, ranging from sperm-egg fusion, to myoblast formation or viral-induced syncytia. 33 To date, only a few studies have directly addressed the role of the tetraspanin web in targeting and uptake of exosomes. Rana et al., discussed the role of tetraspanin family members in biogenesis and cargo selection and binding of exosomes with the target cell. 34 The increased expression of CD151 has been correlated with higher tumor grade and node metastasis in patients with invasive ductal carcinoma of the breast. 35 Essentially, CD151 has been posed to be a significant marker for poor outcome in various cancers. 36 Numerous studies have validated CD151 as a significant prognostic marker of outcome in lung and prostate cancers. 37 
Current status and, most commonly practiced approaches
The specific technologies in isolation of exosomes depend on nonspecific physicochemical properties, particle size, density and solubility. 38 Differential centrifugation is a classical method, widely used for isolation of exosome. However, differential centrifugation causes aggregations of exosomes and contamination from coprecipitated lipoprotein and protein complexes. In recent years, exosome precipitation, magnetic beads and size-exclusion chromatography were developed. 39, 40 However, it remains far from satisfactory due to low purity, which impairs downstream analysis. Nucleic acid testing technologies have progressed immensely in the last two decades to detect exosomes in diverse body fluids. 41 In the recent years, specific antibody-based technologies such as ELISA, flow cytometry, 42 protein microarray, 43 handheld diagnostic magnetic resonance, 23 nanoplasmonic exosome technology 45, 46 and Exoscreen to directly analyze exosomes in the body fluids have been developed. Even though the application of mass spectrometry to clinical practice is in the primary stage, it can provide an accurate concentration of proteins in the exosomes. The major challenges of these technologies include low sample throughput, the variability and complexity of body fluids and complicated sample preparation.
Exosomes in cancer metastasis
Exosomes are emerging as potential intercellular communicators. Exosomes possess molecular signatures like proteins, RNA, lipids or footprints resembling the host cell from which they were secreted. The molecules packed in the tumor exosomes are horizontally transferred into recipient cells, changing their biological properties, modifying their microenvironment and favoring cancer metastasis. Embryonic stem cell-derived microvesicles have been shown to reprogram hematopoietic progenitors by horizontal transfer of pluripotent and early hematopoietic stem cell mRNA. 46 Mast cell-derived exosomes deliver mRNAs and microRNAs to other cells; these RNAs were termed as "exosomal shuttle RNAs". 47 It is suggested that glioblastoma microvesicles promote tumor growth through the transportation of RNAs and proteins. 48 Furthermore, it was identified 33 significantly expressed microRNAs in plasma microvesicles and predicted that these microRNAs may be important factors in the regulation of immune responses and hematopoiesis. 49 Tumor-derived exosomes accumulate in blood and other body fluids, enrich with a selective repertoire of signaling proteins, miRNAs and mRNAs. It was demonstrated that the role of exosomes in enhancing the invasiveness and stemness of naive prostate cancer cells, as well as in promoting cancer-associated fibroblast phenotype in prostate stromal cells. 50 The global miRNA content of cancer exosomes and normosomes has been investigated and a low correlation between the levels of expression of miRNAs in normosomes and nonmetastatic cancer exosomes has been observed. 51 Interestingly, exosomes derived from cancer cells of metastatic origin have been reported to show higher enrichment of miRNAs as compared to exosomes derived from nonmetastatic cancer cells and normal cells. 52 Studies demonstrated that inhibiting the action of Dicer in cancer exosomes significantly impaired tumor growth in recipient cells. 53 They have suggested that tumor exosomes perform cell independent miRNA biogenesis and contribute to tumorigenesis and progression. 51 Reports have shown that tumor cellderived exosomes are capable of delivering mRNAs to recipient cells through clatherin-mediated endocytosis and suggested that it may be a potential pathway of intercellular communication during multiorgan metastasis. 54 
Exosomal tetraspanins in regulation of metastasis
The steps of the metastatic cascade such as evasion from the primary tumor, intravasation, extravasation, settlement and growth in distant organs are well known. 55 Table 1 .
CD 9
By interacting with a variety of proteins, including integrins, signaling proteins and immunoglobulin superfamily members, CD9 suppresses motility and promotes adherence to the surrounding matrix subsequently leading to the suppression of tumor progression. Their expression is often reduced in late-stage human tumors. This has been reported to affect distinct processes in the metastatic cascade. CD9 downregulation has been correlated with tumor progression in several types of cancer. However, CD9 is not strictly classified as a metastasis suppressor gene because in some tumors, a converse activity has been observed. 56 This might be due to the molecules with which it associates. This has been studied using an antibody that preferentially binds to homoclustered CD9, and it was noted that within the cell membrane CD9 homoclustering is promoted by 3 1, 6 4
and by palmitoylation of CD9 and the 4 integrin chain. By contrast, hetero clusters formed by nonpalmitoylated CD9 or CD9 associated with EWI-F and EWI-2 are frequently seen in cancer. 57 endothelial growth factor A and MMP26. Notably, CD9 expression had no effect on the expression of genes involved in cell motility-associated signaling or cell cycle regulation. 58
CD 82
This tetraspanin has been frequently downregulated in advanced stages of cancer and loss of CD82 was first described in rat prostate cancer. 59 CD82 has been shown to strongly associate with a poor prognosis in patients with prostate, gastric, colon, cervical, ovarian, breast, skin, bladder, endometrial, lung, pancreatic, liver and thyroid cancer, melanoma and myeloma. CD82 has been reported to contribute to the hematogenous spread of human lung cancer cells in severe combined immunodeficient mice. 56 Numerous in vitro studies have revealed that overexpression of CD82 results in inhibition of invasion and migration. 60 It has been reported that CD82 interfers with signalling pathway mediated by hepatocyte growth factor receptor (HGFR) by bindig to its receptor HGF. HGFR has been reported to induce proliferation, but cannot induce lamellipodia formation and cell migration in a nonsmall-cell lung cancer line. 61
CD151 (PETA3)
CD151 has been known to promote metastasis in several tumor systems. 62 CD151 supports migration via integrin trafficking, cell motility, adhesion and matrix degradation via protease activity. 63 Interestingly, CD151 knockout animals showed loss of metastatic potential, underlining the necessity of this tetraspanin in metastatic growth. 64 Existing evidence has also shown that CD151 expression is also important for tumor neoangiogenesis and epithelial to mesenchymal transition. Our recent study demonstrated that silencing of CD151 using shRNA inhibits the growth of triple negative breast cancer cells in vitro. 65 Reports showed that glycosylation on 3 1
impedes its association with CD151 and modulates spreading, motility 62 Experimental studies have indicated that they may be important regulators of tumor invasion and metastasis, and high expression of the tetraspanin CD151 has been linked to poor prognosis in a number of cancers. 1 It was reported a spontaneous reduction in the metastatic spread of prostate cancer in a TRAMP model. 67 distribution. 68 In general, exosomal CD151 as a biomarker is still in the early discovery/development stage and its potential value in clinical diagnostics of cancer waits to be fully explored.
TA B L E 2 Expression of CD151 in exosomes of different cancers

Tetraspanin 8
Overexpression of tetraspanin 8, also known as CO-029 and TM4SF3, has been described previously in colorectal, pancreatic and hepatocellular carcinoma which is correlated with poor differentiation and intrahepatic spread of hepatoma. Profiling the tetraspanin web in human colon cancer cells revealed tetraspanin 8 expression in two metastatic cell lines but not in a nonmetastatic cell line. 69 Increased tetraspanin 8 expression in a metastasis versus the primary tumor-derived colon carcinoma line supports a role in tumor progression. 70 Tetraspanin 8 associates with CD9, CD81, CD151 and several integrins, including 3 1 and 6 4. However, the associations between tetraspanin 8 and 3 1 and 6 4 are weaker than those between tetraspanin 8 and CD151. Tetraspanin 8 also associates with nonintegrin partners like EWI-F, EPCAM, CD13, PKC and PI4KII3. 71 Tetraspanin 8 regulates cell motility and survival and is involved in the promotion of angiogenesis. 72 There is strong evidence that tetraspanin 8 promotes motility mostly through its association with 6 4. Tetraspanin 8 has also been shown to promote migration, invasion and metastasis in esophageal cancer owing to its induction of pronounced expression of membrane anchored ADAM12.
Exosomes in cancer diagnosis
Exosomes have emerged as a new paradigm of noninvasive cancer diagnosis and monitoring of treatment response. The exosomal surface markers distinguish tumor-derived exosomes from normal exosomes by contributing to specificity in diagnosis. Although studies on exosomes have begun since several decades, their utilization as diagnostic markers is a relatively new field. Recently, researchers have found some molecules in the exosomes with great potential to utilize as a platform for personalized diagnostics. 43 Some of the molecules associated with tumor prognosis also exploited as biomarkers of personalized diagnostics. 73, 74 Exosome containing the surface protein, glypican-1, was used for detection of pancreatic cancer with 100% accuracy using 150-200 L of blood. 43 The presence of mobile heterogeneity or tumor-derived exosomes in blood not only offers cancer diagnosis, but it can also perform real-time therapy response monitor- 76 It has been previously reported that levels of EpCAM and survivin proteins are higher in the exosomes of body fluids of metastatic breast cancer patients, thereby, making them as metastatic breast cancer biomarkers. 77 Earlier, membrane transporters and fusion proteins, heat shock proteins, tetraspanins and lipid-related proteins have been identified in some exosomes using an exosome database (Version 4; http://www.exocarta.org). 38 The potential and feasibility of exosome-based diagnosis is reinforced by a number of publications. Several cancer exosomal markers are associated with the state of tumor.
Exosomal tetraspanins as diagnostic markers
Tetraspanins play a key role in the formation of TEM, which also contain a number of other transmembrane receptors like integrins, receptors and tyrosine kinases. These integrin-tetraspanin complexes play a critical role during metastatic progression by controlling cell-cell interactions and regulating cell invasiveness. 78 It was demonstrated exosomal tetraspanins as biomarkers for early detection of oral cancer. 79 Studies demonstrated that exosomal tetraspanin family proteins serve as an important marker for colorectal cancer. 80 Based on their own findings, it was hypothesized that exosomes expressing a defined set of tetraspanins and associated molecules target endothelial cells, thereby contributing to angiogenesis and vasculogenesis. 81 Studies demonstrated that tetraspanin complexes form cholesterol-associated microdomains that are distinct from lipid rafts in platelets. 17 Squamous carcinoma cells secrete exosomes and exosome-associated proteins with the potential to modulate their microenvironment and facilitate angiogenesis and metastasis. 82 Exosomal proteins, including tetraspanins, may provide insights into colon cancer biology and potential diagnostic biomarkers by overexpression of molecular signatures of exosomes such as coiled coil, RAS and MIRO domains. 83 Glioblastoma and astrocyte cells were found to release exosomes with characteristic tetraspanins, which carry mitochondrial DNA. 84 Tetraspanin family proteins, CD9, CD63 and CD81 have been reported as collection markers of exosomes. [85] [86] [87] Exosomal tetraspanins were used as a tool in understanding the mechanism of exosome formation, release and function in prostate cancer. 88 Studies have found that liver-specific antiproliferative miRNA is transferred via exosomes between cocultured human hepatoma cells, Huh7 and HepG2. 89 Some reported the use of urinary exosomal protein, WT1
as early noninvasive marker for diabetic nephropathy. 90 It has been observed that tumor-derived exosomes modulate TME by transfer of macromolecules both locally as well as to distant metastatic sites. 91 Unfortunately, many surface markers are shared by exosomes derived from various cancer cell lines and between tumor and nontumor tissues. The tetraspanin CD151, also known as PETA-3 (plateletendothelial cell tetraspanin antigen 3), SFA-1 (SF-HT activated gene 1) or Tspan24, is widely expressed in several cell types, including epithelial, endothelial, muscle and hemopoeitic cells. 92 CD151 expression has been investigated in tumor tissues from gastric, colorectal, prostate, pancreatic, breast and hepatocellular cancer patients. 93, 94 Elevated expression was observed in patients with advanced disease, and higher levels of expression were found retrospectively to be associated with poorer prognosis. The function of CD151 is not well understood, but it has been shown to interact with different membrane and intracellular proteins, and thus to be implicated in different transmembrane signaling pathways and cell functions. 56 
CONCLUSION
There is an unmet clinical need for the detection of robust prognos- 
